Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02426125 · MORE INFO

Limitations, agreements, and source contact

A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer · Source last updated 2023-08-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restriction Type
GT60
restrictive Agreement
true
point Of Contact
email
ClinicalTrials.gov@lilly.com
organization
Eli Lilly and Company
phone
800-545-5979
title
Chief Medical Officer
Complete source fields
certain Agreement
pi Sponsor Employee
false
restriction Type
GT60
restrictive Agreement
true
point Of Contact
email
ClinicalTrials.gov@lilly.com
organization
Eli Lilly and Company
phone
800-545-5979
title
Chief Medical Officer

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice